Table 3 Immunophenotypic and molecular features of patients with noninvasive BI EBV+ LBCL and breast implant ALCL.
Marker | BI EBV+ LBCL (n = 7) | Breast-implant ALCL (n = 14) |
|---|---|---|
CD3 | 0/5 (0%) | 3/14 (21%) |
CD4 | 0/2 (0%) | 10/14 (71%) |
CD5 | 0/5 (0%) | 2/12 (16%) |
CD8 | 0/2 (0%) | 2/14 (14%) |
CD10 | 0/7 (0%) | 0/4 (0%) |
CD15 | 1/2 (50%) | 4/8 (50%) |
CD20 | 7/7 (100%) | 0/10 (0%) |
CD30 | 6/7 (85%) | 14/14 (100%) |
CD30, intensity | ||
1+ | 2 (33%) | 0 (0%) |
2+ | 3 (50%) | 0 (0%) |
3+ | 1 (17%) | 14 (100%) |
CD30, extent | ||
Most lymphoma cells | 3 (50%) | 14 (100%) |
Subset lymphoma cells | 3 (50%) | 0 (0%) |
CD30, pattern | ||
Cytoplasmic only | 2 (34%) | 0 (0%) |
Cytoplasmic and membrane | 4 (66%) | 14 (100%) |
CD43 | 1/2 (50%) | 5/9 (55%) |
CD45 | 7/7 (100%) | 3/9 (33%) |
CD79a | 7/7 (100%) | 0/4 (0%) |
CD138 | 0/5 (0%) | NA |
ALK | 0/7 (0%) | 0/14 (0%) |
BCL6 | 1/5 (20%) | 0/1 (0%) |
Epithelial membrane antigen | 0/2 (0%) | 8/10 (80%) |
Epstein–Barr virus (EBV) | ||
EBERa | 7/7 (100%) | 0/7 (0%) |
EBV LMP-1 | 7/7 (100%) | NA |
EBV EBNA-2 | 7/7 (100%) | NA |
Latency pattern type III | 7/7 (100%) | NA |
Granzyme B | 0/1 (0%) | 5/10 (50%) |
HHV-8 | 0/7 (0%) | 0/7 (0%) |
Ki-67 (%), median | 80% | 90% |
MUM-1/IRF4 | 7/7 (100%) | 3/3 (100%) |
MYC | 5/6 (83%) | NA |
PAX5 | 6/6 (100%) | 0/5 (0%) |
TIA-1 | 0/1 (0%) | 7/9 (77%) |
Clonality studies | ||
IGHb | 3/3 (100%) | NA |
TRB or TRGb | NA | 6/6 (100%) |
